Myasthenia Gravis clinical trials

Explore recruiting myasthenia gravis clinical trials.

Recruiting myasthenia gravis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myasthenia Gravis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC)

Denmark, Poland, France, Netherlands, Norway, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

Portugal, France, Poland, Austria, Spain, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

Germany, Denmark, Sweden

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Norway, Poland, Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ACTIVITY OF ZILUCOPLAN IN PEDIATRIC STUDY PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR ANTIBODY POSITIVE GENERALIZED MYASTHENIA GRAVIS

Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)

Italy, Poland, France, Germany, Spain, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Myasthenia Gravis trials by city

Myasthenia Gravis in Toronto Myasthenia Gravis in Vancouver Myasthenia Gravis in Montreal Myasthenia Gravis in Calgary Myasthenia Gravis in Edmonton Myasthenia Gravis in Ottawa Myasthenia Gravis in Winnipeg Myasthenia Gravis in Quebec City Myasthenia Gravis in Hamilton Myasthenia Gravis in Kitchener Myasthenia Gravis in London Myasthenia Gravis in Halifax Myasthenia Gravis in New York Myasthenia Gravis in Los Angeles Myasthenia Gravis in Chicago Myasthenia Gravis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease